- Home
- CYBN vs NVCT Comparison
CYBN vs NVCT Comparison
Compare CYBN & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- NVCT
- Stock Information
- Founded
- CYBN 2019
- NVCT 2020
- Country
- CYBN Canada
- NVCT United States
- Employees
- CYBN N/A
- NVCT N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- CYBN Health Care
- NVCT Health Care
- Exchange
- CYBN Nasdaq
- NVCT Nasdaq
- Market Cap
- CYBN 180.4M
- NVCT 184.9M
- IPO Year
- CYBN N/A
- NVCT 2022
- Fundamental
- Price
- CYBN $7.61
- NVCT $8.02
- Analyst Decision
- CYBN Strong Buy
- NVCT Strong Buy
- Analyst Count
- CYBN 4
- NVCT 3
- Target Price
- CYBN $85.00
- NVCT $17.00
- AVG Volume (30 Days)
- CYBN 387.1K
- NVCT 179.3K
- Earning Date
- CYBN 08-07-2025
- NVCT 08-05-2025
- Dividend Yield
- CYBN N/A
- NVCT N/A
- EPS Growth
- CYBN N/A
- NVCT N/A
- EPS
- CYBN N/A
- NVCT N/A
- Revenue
- CYBN N/A
- NVCT N/A
- Revenue This Year
- CYBN N/A
- NVCT N/A
- Revenue Next Year
- CYBN N/A
- NVCT N/A
- P/E Ratio
- CYBN N/A
- NVCT N/A
- Revenue Growth
- CYBN N/A
- NVCT N/A
- 52 Week Low
- CYBN $4.81
- NVCT $4.44
- 52 Week High
- CYBN $13.88
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- CYBN 46.51
- NVCT 49.93
- Support Level
- CYBN $7.35
- NVCT $7.56
- Resistance Level
- CYBN $7.85
- NVCT $8.27
- Average True Range (ATR)
- CYBN 0.60
- NVCT 0.39
- MACD
- CYBN -0.10
- NVCT 0.08
- Stochastic Oscillator
- CYBN 18.20
- NVCT 89.52
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.